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Abstract
Background: Overexpression of the human DYRK1A gene due to the presence of a third gene
copy in trisomy 21 is thought to play a role in the pathogenesis of Down syndrome. The
observation of gene dosage effects in transgenic mouse models implies that subtle changes in
expression levels can affect the correct function of the DYRK1A gene product. We have therefore
characterized the promoter of the human DYRK1A gene in order to study its transcriptional
regulation.
Results: Transcription start sites of the human DYRK1A gene are distributed over 800 bp within a
region previously identified as an unmethylated CpG island. We have identified a new alternative
noncoding 5'-exon of the DYRK1A gene which is located 772 bp upstream of the previously
described transcription start site. Transcription of the two splicing variants is controlled by non-
overlapping promoter regions that can independently drive reporter gene expression. We found
no evidence of cell- or tissue-specific promoter usage, but the two promoter regions differed in
their activity and their regulation. The sequence upstream of exon 1A (promoter region A) induced
about 10-fold higher reporter gene activity than the sequence upstream of exon 1B (promoter
region B). Overexpression of the transcription factor E2F1 increased DYRK1A mRNA levels in
Saos2 and Phoenix cells and enhanced the activity of promoter region B three- to fourfold.
Conclusion: The identification of two alternatively spliced transcripts whose transcription is
initiated from differentially regulated promoters regions indicates that the expression of the
DYRK1A gene is subject to complex control mechanisms. The regulatory effect of E2F1 suggests
that DYRK1A may play a role in cell cycle regulation or apoptosis.
Background
Protein kinases of the DYRK (dual specificity tyrosine
phosphorylation-regulated kinase) family play key roles
in the regulation of cell growth and differentiation in a
variety of systems [1,2]. Processes controlled by DYRKs
include the organization of the symmetric cell division in
S. pombe [3], the transition from growth to development
in Dictyostelium [4], the formation of the embryonic axis
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mammals [6]. In Drosophila, the kinase encoded by the
minibrain gene (MNB) plays an essential role in postem-
bryonic neurogenesis [7], and the orthologous proteins in
chicken (MNB) and mammals (DYRK1A) have also been
implicated in the regulation of neuronal differentiation
(reviewed in [8]). Because the human DYRK1A gene is
localized within a region of chromosome 21 considered
to be particularly important for many traits of Down syn-
drome ("Down syndrome critical region") [9,10],
DYRK1A has attracted interest as a candidate gene for
brain abnormalities and mental retardation in individuals
with Down syndrome.
The proposed role of DYRK1A in Down syndrome-related
mental retardation was supported by analyses of geneti-
cally altered mice. Three different mouse models (trans-
genic mice with a yeast artificial chromosome that
includes the human DYRK1A gene, transgenic mice over-
expressing the cDNA of rat Dyrk1a, and transgenic mice
with one extra copy of the human DYRK1A gene in a bac-
terial artificial chromosome) were generated and found to
exhibit neurodevelopmental delays and impairment in
learning tasks [11-13]. Interestingly, mice heterozygous
for Dyrk1a also show marked abnormalities of brain
development and behavior [14-17], providing evidence
that the function of DYRK1A is particularly sensitive to
gene dosage effects. It is generally thought that the many
features of Down syndrome originate from a 1.5-fold
increase in the dosage of genes in the Down syndrome
critical region [18]. Expression of the human DYRK1A was
shown to be increased 1.5-fold in fetal and adult brains
from subjects with Down syndrome [19-21].
These results imply that the function of DYRK1A is
strongly influenced by its level of expression. The activity
of many protein kinases is subject to short term control by
second messengers (Ca2+, cAMP, AMP), posttranslational
modifications such as phosphorylation, or interaction
with regulatory subunits (cyclins, CDK). In contrast,
DYRKs require phosphorylation of a conserved tyrosine
residue in the activation loop to acquire maximal catalytic
activity, but this is an autophosphorylation event that
takes place during maturation of the protein and does not
appear to be subject to regulation [22,23]. Although the
activity of DYRK1A has been reported to be modulated by
bFGF (basic fibroblast growth factor) [24] and by interac-
tion with 14-3-3 proteins [25], the kinase was found to be
constitutively active in all systems studied so far. Hence,
regulation of gene expression will directly influence the
cellular function of DYRK1A. Microarray studies have
revealed striking changes in the abundance of DYRK1A
mRNA in various systems of cellular differentiation and
proliferation, e.g., during activation of T-cells [26], in
human neutrophils exposed to bacteria [27], in differenti-
ating haematopoetic progenitor cells [28], in the course of
melanoma tumor progression [29], or in HPV16-immor-
talized keratinocytes [30]. Interestingly, expression of
DYRK1A is also tightly controlled in neural progenitor
cells of early developing chicken brains [31]. Altogether,
these studies clearly indicate that DYRK1A mRNA levels
are highly regulated, although the question how the
expression of the DYRK1A gene is controlled has not been
directly addressed until now.
In this study we have characterized the promoter of the
human DYRK1A gene in order to analyze its transcrip-
tional regulation. Our data show that transcription of the
DYRK1A gene can start within a broad region of 800 bp.
Two non-overlapping regions within the 5'-region of the
DYRK1A gene exhibit promoter activity in reporter gene
assays and lead to transcripts with alternative noncoding
5' exons. Interestingly, one of the two promoter regions is
regulated by the transcription factor E2F1, suggesting a
potential role of DYRK1A in the cell cycle.
Results
Alternative transcription start sites in the human DYRK1A 
gene
We performed RACE-PCR on cDNA from the human PC3
prostate carcinoma cell line. Sequencing of cloned PCR
products revealed three types of cDNAs. The shortest
clones contained cDNA fragments with their 5'-ends on
exon 2 upstream of the initiator codon (transcript a in Fig-
ure 1). We considered these cDNAs to be truncated
because several longer transcripts were already known.
Second, larger products (b in Figure 1, represented by four
RACE clones) contained cDNA fragments that started 11
nucleotides upstream of the "type 1" transcript described
by Wang et al. [32] [GenBank:AB015283] and 14 nucle-
otides downstream of the transcription start of the
MNBHa transcript that was previously identified by Gui-
mera et al. [19] [GenBank:AF108830]. None of the RACE
products from the PC3 cells corresponded to the alterna-
tively spliced MNBHb transcript that was also described in
the latter paper. However, we identified two independent
clones that contained a short piece of sequence from bp -
772 to -756 that was directly spliced to exon 2 (c in Figure
1; for detailed sequence information see Figure S1 in the
Additional file 1 "supplementary figures").
To confirm the existence of this alternatively spliced tran-
script, we performed PCR with a specific forward primers
matching exon 1A and reverse primers for exon 3 (Figure
2). In parallel, a forward primer specific for exon 1B was
used with the same reverse primers. We used cDNA from
the human osteosarcoma cell line Saos2 as a template to
exclude the possibility that the alternative transcript was
an aberrant splice product specific to PC3 cells. All primer
pairs yielded major amplification products that repre-Page 2 of 16
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Mapping of transcripts to the 5'-region of the human DYRK1A geneFigure 1
Mapping of transcripts to the 5'-region of the human DYRK1A gene. A schematic representation of the exon-intron 
organization is shown on top. Exons are numbered (1M, 1A, 1B, 2 and 3) and drawn to scale. Open boxes are noncoding 
regions, filled boxes represent the coding sequence. Open boxes with dotted lines are facultative exonic sequences that have 
been described in previous reports. Numbering of nucleotides in the promoter region refers to the 5'-end of transcript 
MNBHa which has previously been defined as the transcription start of the human DYRK1A gene [19] and corresponds to the 
transcript variant 3 (NM_101395) in the NCBI database. Position +1 corresponds to hchr21:37,661,729 in the assembly at the 
UCSC genome browser (release hg18). A CpG island identified by Yamada et al. [33] is indicated, with the bar representing the 
region that was analyzed in this report and found to be unmethylated. DYRK1A transcript variants that were previously 
described by Guimera et al. 1999 [19] or Wang et al. 1998 [32](database accession numbers are given in brackets) or were 
identified by 5'-RACE in the present study (a, b, c) are depicted thereunder. Positions of the primers used for RACE are indi-
cated by arrows.
BMC Molecular Biology 2008, 9:30 http://www.biomedcentral.com/1471-2199/9/30sented the expected transcripts (as indicated in the top
panel of Figure 2). For each of the alternatively spliced
first exons, the major bands in one of the PCRs (from
lanes 2 and 4) were cloned and verified through sequenc-
ing. In addition, minor fragments were detected that were
about 100 bp larger or smaller (very faint bands on the gel
shown in Figure 2), and are derived from alternatively
spliced transcripts (see below). The same pattern of bands
was obtained by PCR on cDNA from PC3 cells (not
shown).
None of the RACE or PCR products that we obtained con-
tained the alternatively spliced additional exons between
exon 1B and exon 2 that were identified by Guimera et al.
[19] [GenBank:AF108830] and Wang et al. [32] [Gen-
Bank:AB015284] (see Figure 1). However, one of our
RACE clones contained two additional exons between
exon 2 and exon 3 (for detailed sequence information, see
Figure S1 in the Additional file 1 "supplementary fig-
ures"). In addition, a clone derived from the upper band
in lane 4 of the gel presented in Figure 2 contained
another alternative exon between exon 2 and exon 3 (see
Figure S2 in the Additional file 1 "supplementary fig-
ures"). These facultative exons are flanked by bona fide
consensus splicing sites, but neither exon shows sequence
conservation between rodents and human and they are
not supported by expressed sequence tags in the database;
furthermore, both contain premature termination
codons. The smallest band produced by the PCR in Figure
2 represented a transcript in which exon 1B was directly
spliced to exon 3, as in the clone [GenBank:AB015282]
[32] (Figure 1). This transcript lacks the initiator codon on
exon 2 and therefore would encode an N-terminally trun-
cated version of DYRK1A, if another ATG codon could
function as an alternative initiation codon. The relevance
of these minor splicing variants is unclear.
Structure of the DYRK1A promoter
The present results provide evidence of two transcription
start sites separated by 772 bp in the 5'-region of the
human DYRK1A gene. These start sites initiate two alter-
natively spliced transcripts that differ in their 5'-untrans-
lated sequences, but are identical within their coding
regions. The sequence of this region and the exact posi-
tions of the transcription start sites are shown in Figure S1
(in the Additional file 1 "supplementary figures"). We
designate the alternative first exons of these transcripts
exon 1A and 1B, respectively, and the corresponding tran-
scription start sites TSS A and TSS B. Both start sites are
devoid of canonical TATA or CAAT boxes, but the whole
region is very GC-rich and contains numerous potential
binding sites for the transcription factor Sp1 (Figure S1).
TSS B lies within a CpG island that was previously found
to be unmethylated in a comprehensive analysis of the
methylation status of CpG islands on human chromo-
some 21 (#61 in Ref. [33]).
No PCR product was identified that started at TSS A and
contained the whole sequence up to exon 1B. However,
we cannot exclude that such transcripts escaped detec-
tion because the shorter variant might have been posi-
tively selected during PCR. TSS B is identical to the 5'-
end of the MNBHa transcript described by Guimera et al.
[19]. We designate the first exon of the MNBHb tran-
script proposed by Guimera exon 1M because this tran-
script was reported to be specifically expressed in
muscle.
Chromatin organization in the 5'-region of the human 
DYRK1A gene
Barski et al. [34] have recently generated a genome-
wide, high resolution map of histone methylation and
chromatin organization in resting human CD4+ T-cells
through chromatin immunoprecipitation sequencing
analysis (ChIP-Seq). The results for the DYRK1A gene
within this dataset show that the highest level of RNA
RT-PCR analysis of the alternatively spliced DYRK1A tran-scriptsFigure 2
RT-PCR analysis of the alternatively spliced DYRK1A 
transcripts. Forward primers specific for either exon 1A 
(1Afor) or exon 1B (1Bfor) were used for PCR together with 
either one of two reverse primers targeting exon 3 (upper 
panel). First-strand cDNA was subjected to RT-PCR analysis 
with the indicated primers, and reaction products were visu-
alized by ethidium bromide staining (lower panel). The 
lengths of the marker bands are indicated in bp. Expected 
fragment lengths are 192 bp, 232 bp, 216 bp and 256 bp for 
lanes 1–4. Arrows point to PCR products that were cloned 
and sequenced.Page 4 of 16
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exon 1A/1B (see Figure S3 in the Additional file 1 "sup-
plementary figures"). Other characteristics typical of
active promoters, e.g,. the presence of the histone
H2A.Z and of histone H3 that is trimethylated on Lys4,
were also specifically detected in this region. The region
upstream of exon 2, which was regarded as the pro-
moter of the DYRK1A gene in previous studies [35-37],
exhibits neither the characteristics of an active nor an
inactive promoter (e.g., binding of H3 trimethylated on
Lys27; [34]).
Transcription start sites of the human DYRK1A gene in 
the CAGE database
To further define the heterogeneity of transcription start
sites in the DYRK1A promoter, we took advantage of the
cap-analysis of gene expression (CAGE) database of tran-
scription start sites that was established by the FANTOM
consortium [38]. CAGE tags are derived from capped
mRNA molecules and thus represent the 5'-ends of indi-
vidual transcripts. In total, 420 CAGE tags mapped to the
human DYRK1A gene (transcriptional unit 723 in the
database, 148,314 bp). Of these, 234 tags mapped to the
1,000 bp-region upstream of TSS B, whereas only two tags
Mapping of CAGE tags to the human DYRK1A promoterFigure 3
Mapping of CAGE tags to the human DYRK1A promoter. The CAGE database was searched for tags ascribed to the 
human DYRK1A gene (upper panel) and the murine Dyrk1a gene (lower panel) with the help of the CAGE basic viewer. All tags 
located within a region of 1,000 bp upstream of TSS B were selected, and the numbers of tags with 5'-ends at one specific 
nucleotide position were plotted vs. the position relative to TSS B. Major tag clusters (> 10 tags) as defined by Carninci et al. 
[39] are highlighted by coloring, and the number of tags forming this cluster is indicated. The region marked by a grey bar in the 
murine promoter was not sequenced in the genome sequence assembly (mouse May 2004) on which the CAGE tags were 
mapped.
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and no tags mapped to the 5,000 bp upstream of exon 2.
Carninci et al. [39] have grouped CAGE tags into tag clus-
ters (TC) that were operationally defined to characterize
promoters. As illustrated in Figure 3, major tag clusters are
located close to TSS A and TSS B, respectively, confirming
that the RACE clones obtained in our study represent
major transcription start sites. In addition, a considerable
number of tags, including the largest tag cluster of the
DYRK1A gene (84 CAGE tags), map to the region between
TSS A and TSS B. Given that each CAGE tag represents the
true 5'-end of an individual mRNA molecule, this analysis
shows that transcription of the DYRK1A gene can initiate
within a broad region of about 800 bp. There was no dif-
ference in tissue distribution between the CAGE tags
belonging to the different tag clusters. This unusual broad
distribution of transcription start sites was also found in
mouse tissues (Figure 3B), indicating that it is conserved
feature of this gene.
Promoter activities of human DYRK1A 5'-regions
We cloned a 827 bp-sequence upstream of human exon
1M (bp -2726 to -1899), a 681 bp-region upstream of
exon 1A, and a 1453 bp-region upstream of exon 1B in
order to characterize their promoter activities in reporter
gene assays. In addition, we generated a series of deletion
constructs of the 1453-bp sequence in order to localize
regulatory sequence elements and the minimal promoter
region. The results of the luciferase assays in the human
osteosarcoma cell line Saos2 clearly show that the two
non-overlapping regions upstream of TSS A (-1453 to -
756) and TSS B (-742 to +44) were able to independently
drive reporter gene expression (Figure 3). Promoter region
A was 14-fold more active than promoter region B, and
the promoter activity of all constructs including both TSS
A and TSS B was consistently higher than of those contain-
ing only TSS B. The lower activity of the -1453/+44 con-
struct as compared to the -1453/-756 construct is possibly
due to the fact that in the full length construct, transcrip-
tion from TSS A proceeds through the whole region
between TSS A and TSS B. Also, the presence of the unusu-
ally long 5'-UTR (which is normally spliced out from the
endogenous transcripts) may impede efficient translation.
In contrast to the regions upstream of TSS A and TSS B, the
putative promoter region upstream of exon 1M did not
stimulate luciferase activity in Saos2 cells. The same result
was obtained in COS7 cells (data not shown), and this
region was not studied further in the present work.
Because of the muscle-specific expression of exon 1M con-
taining transcripts, functional analysis of the promoter
region might require the use of a myoblast cell line.
Figure 4 demonstrates that two parts of the sequence
appear to be particularly important for promoter activity:
Deletion of the segments between -839 and -742 or
between -324 and -226 caused marked decreases of luci-
ferase activity. However, a short segment of 114 bp
upstream of TSS B was still sufficient to induce luciferase
expression more strongly (3.2-fold) than the promoterless
vector, and thus may be considered the minimal promoter
region of TSS B.
Upregulation of DYRK1A by E2F1
In two independent microarray studies, DYRK1A was
among the genes upregulated by overexpression of the
transcription factor E2F1 in the human U2OS osteosar-
coma cell line [40] and in murine NIH3T3 fibroblasts
[41]. To confirm these results, we analyzed the effect of
E2F1 overexpression on DYRK1A mRNA levels in Phoenix
cells. This cell line is a derivative of human embryonic
kidney cells (HEK), and was chosen for this experiment
because it allows efficient transient transfection and has
previously been used for analysis of E2F1 effects [42]. As
shown in Figure 5A, overexpression of E2F1 in Phoenix
cells caused a marked increase of DYRK1A mRNA levels.
To confirm this result in a different cell line, we took
advantage of a Saos2 cell clone that allows tetracycline-
regulated overexpression of E2F1 [43]. Again, DYRK1A
mRNA was upregulated upon induction of E2F1 overex-
pression.
E2F1 specifically enhances activity of promoter region B
Next we determined the effect of E2F1 on the promoter
activities of the DYRK1A reporter gene constructs in Saos2
cells. As shown in Figure 6A, induction of E2F1 expression
by doxycycline caused a four-fold increase in the pro-
moter activity of all constructs containing only promoter
region B but did not significantly affect constructs con-
taining TSS A. Note that because of their higher basal
activities (see Figure 3), constructs containing TSS A
exhibited even higher promoter activities than the E2F1-
stimulated constructs containing only TSS B. Therefore,
the E2F1 effect was not detectable with constructs contain-
ing both TSS A and TSS B.
Next we asked whether the murine Dyrk1a promoter was
also regulated by E2F1. For a direct comparison of human
and murine promoters, reporter gene vectors including
either TSS A or B were analyzed side by side in Saos2 cells.
This experiment showed that the basal activities of
homologous promoter constructs for TSS A and TSS B
were very similar (Figure 6B). Like in the human pro-
moter, two non-overlapping fragments of the murine pro-
moter are capable of driving reporter gene expression, and
also similar to the human promoter, promoter region A
shows about 10-fold (12.3 ± 2.0 mean ± SD) higher activ-
ity than promoter region B. Overexpression of E2F1
enhanced the activity of promoter region B (-660 frag-
ment), as was also observed with the human promoterPage 6 of 16
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for an E2F1 effect on promoter region B, our data do not
exclude the possibility that E2F1 can also affect transcrip-
tion from TSS A because weak stimulatory effects may
have been masked by the higher basal activity of these
promoter constructs.
Mutational analysis of putative E2F1 and Sp1 binding sites 
in promoter region B
Inspection of the 1453 bp-sequence upstream of TSS B
revealed a putative E2F1-binding site at -153 that matched
the criteria of a consensus sequence (Figure 7A). We gen-
erated a point mutation of this motif in the -742 reporter
gene construct that is driven by the E2F1-responsive pro-
moter B. In addition, we mutated two Sp1 sites immedi-
ately upstream of TSS B because Sp1 and E2F1 can interact
in the regulation of GC-rich promoters [44-46]. Luciferase
assays were performed in Saos2 cells as before to analyze
potential effects of these mutations. As shown in Figure
7B, neither the basal nor the E2F1-induced promoter
activity was significantly changed by the mutations.
Therefore, the three sites are not essential for the regula-
tion of TSS B by E2F1.
Putative CREB binding site in the DYRK1A promoter
In a genome-wide screen for target genes of cAMP-
response element binding protein (CREB), Impey et al.
[47], through a chromatin immunoprecipitation based
method, identified Dyrk1a as a gene close to which CREB
was bound in forskolin-stimulated rat PC12 cells. Further-
more, microarray analysis found Dyrk1a mRNA to be
upregulated by forskolin. Because CREB is critically
involved in synaptic plasticity and learning [48], we
decided to study the proposed effect of CREB on the
Dyrk1a promoter. The canonical cAMP-response element
(CRE) is an eight-base palindrome (TGACGTCA) but
CREs also frequently occur as half-site motifs (CGTCA)
[49]. A sequence motif comprising one CRE sequence
with a single mismatch and a neighboring half-site is
present about 50 bp upstream of TSS A (Figure 8A). This
Deletion analysis of the DYRK1A promoter regionFigure 4
Deletion analysis of the DYRK1A promoter region. Fragments of the 5'-flanking regions of the human DYRK1A gene 
were fused to the firefly luciferase cDNA in the vector pGL3basic. The position of the promoter fragments relative to TSS B 
(+1) is indicated. Segments upstream of TSS A and TSS B are highlighted in red and blue, respectively. Saos2 cells were co-
transfected with the indicated reporter gene constructs and a β-galactosidase reporter control plasmid. Cells were lysed 48 h 
after transfection, and luciferase activities were determined from duplicate wells. Data were normalized to β-galactosidase 
activities and are presented as the ratio relative to the activity of the -742 construct. The diagram integrates results of 2–6 
independent experiments. Bars reflect means +/- SD. The inset shows a magnified representation of the weakest signals.
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ing mice (the sequence in rats is not yet known).
Therefore we analyzed whether Dyrk1a mRNA is regulated
by intracellular cAMP levels. Forskolin is an activator of
adenylate cyclase, and the increased cAMP levels cause the
phosphorylation of Ser133, and consequently the activa-
tion of CREB by cAMP-dependent protein kinase (Figure
8B). However, treatment of PC12 cells with forskolin did
not change Dyrk1a mRNA levels in PC12 cells, as revealed
by Northern blot analysis (Figure 8C). The same result
was obtained in an experiment with a PC12 clone from a
different source (data not shown). As a control, a known
target gene of CREB, the protooncogene c-fos [50], was
readily induced by forskolin. In spite of this negative
result, we performed reporter gene assays in order to
assess the effect of forskolin on the activity of promoter
region A. No stimulation of either promoter region A or B
by forskolin was observed in three different cell lines (Fig-
ure 8D). In contrast, a synthetic reporter gene construct
driven by four consecutive CREs was stimulated by forsko-
lin, indicating that the cell lines analyzed were capable of
a transcriptional response to forskolin/cAMP. Finally, we
performed an electrophoretic mobility shift assay with
nuclear extracts from forskolin-treated PC12 cells to deter-
mine whether CREB can bind to the CRE motif in pro-
moter region A. As shown in Figure S4 (in the Additional
file 1 "supplementary figures"), the probe derived from
the DYRK1A gene was detected in CREB-containing com-
plexes but the intensity of the bands was much weaker
that of those with the consensus CRE.
Discussion
DYRK1A has attracted considerable interest as a "candi-
date gene" potentially responsible for several traits related
to Down syndrome. Although the characterization of
transgenic mouse models has shown that the correct func-
tion of this protein kinase is critically dependent on the
gene dosage and, consequently, the intracellular level of
the DYRK1A protein, nothing is known about its regula-
tion on the level of gene expression. The present study
provides the first functional characterization of the
human DYRK1A promoter.
The structural organization of the human DYRK1A gene
has previously been described by Wang et al. [32] and
Guimera et al. [19], who have also identified transcripts
with 5'-ends in the promoter region. In other reports, the
region upstream of exon 2 was regarded as the promoter
[35-37], probably because their in silico-methods for pro-
moter identification failed to correctly recognize the first
non-coding exon. Of the five transcript in the NCBI Core-
Nucleotide database, only transcript 3 (Gen-
Bank:NM_101395) begins with exon 1B, whereas the
others have 5'-ends at exon 2. The analysis of chromatin
organization in the human DYRK1A gene (Fig. S3 in the
Additional file 1 "supplementary figures") provides clear
evidence that only the region around exons 1A and 1B
exhibits features of an active promoter. The distribution
of CAGE tags also shows no evidence of a promoter
upstream of exon 2. Here we describe a new transcription
start site (TSS A) which belongs to an alternative first
exon (exon 1A) located 772 bp upstream of the known
TSS B. Both transcript variants encode the same protein,
but their expression is controlled by different promoter
sequences. In addition to these two transcription start
sites, evaluation of the CAGE tag database revealed that
transcription can start at many more different sites
within the region between TSS A and B. According to the
working definition used by Carninci et al. [39], the pro-
moter region of the human DYRK1A gene encompasses 5
non-overlapping CAGE tag clusters that by definition
should represent alternative promoters (Figure 2). Each
of these clusters displays a broad distribution of start
sites, and according to the classification of Carninci et al.
[39] the overall distribution can be described as "broad
with dominant peaks" (-252 to -814) plus an extra cluster
at TSS B (-11 to -35). It remains to be determined
Upregulation of DYRK1A mRNA by E2F1 overexpressionFigure 5
Upregulation of DYRK1A mRNA by E2F1 overex-
pression. A) Phoenix cells were transfected with an expres-
sion plasmid for E2F1 (2 μg/10 cm plate) or vector DNA 
(Ctrl). Total RNA was isolated 2 days after transfection and 
subjected to Northern blot analysis with probes for 
DYRK1A and GAPDH as indicated. Ethidium bromide-
stained bands of the ribosomal RNAs are shown as a loading 
control. B) Saos2 cells expressing E2F1 under the control of 
a doxycycline-inducible promoter were treated for 18 h with 
doxycycline (E2F1), or were not treated (Ctrl) before the 
RNA was isolated. Duplicate lanes contain RNA from parallel 
plates.
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BMC Molecular Biology 2008, 9:30 http://www.biomedcentral.com/1471-2199/9/30whether the tag clusters between TSS A and TSS B, in par-
ticular the largest cluster at about -500, represent inde-
pendent core promoters.
The extended distribution of TSS is typical for promoters
that lack a TATA-box and contain transcription start sites
within CpG islands [39]. The region of the DYRK1A pro-
moter has previously been classified as an unmethylated
E2F1 enhances reporter gene activity of promoter region BFigure 6
E2F1 enhances reporter gene activity of promoter region B. A) The inducible E2F1-expressing Saos2 cells were trans-
fected with deletion constructs of the human DYRK1A promoter as indicated. Five hours after transfection, the medium was 
changed and cells were treated with doxycycline or were not treated. Data were normalized to β-galactosidase activity and are 
expressed as fold stimulation relative to untreated cells. The diagram integrates results of 2–6 independent experiments, and 
bars reflect the means +/- SD. B) Luciferase constructs of the human DYRK1A and the murine Dyrk1a promoter were analyzed 
for upregulation by doxycycline-induced overexpression of E2F1. Data were normalized to β-galactosidase activity and are pre-
sented as the ratio relative to the activity of the unstimulated murine -660 construct. Bars reflect the means +/- SD of 3 inde-
pendent experiments.
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Mutational analysis of potential E2F1 binding sitesFigure 7
Mutational analysis of potential E2F1 binding sites. A) Point mutations introduced into the -742 promoter construct in 
order to eliminate possible E2F1 binding sites. B) The inducible E2F1-expressing Saos2 cells were transfected with the -742 
promoter construct or the mutated versions thereof as indicated. Five hours after transfection, the medium was changed and 
cells were treated with doxycycline or were not treated. Data were normalized to β-galactosidase activity and are presented 
as the ratio relative to the activity of the unstimulated wild type construct. Luciferase activity of induced cells was significantly 
different from that in untreated cells (two-sided t test, p < 0.05, except for the double mutant) but there was no significant dif-
ference between wild type and mutants. Bars reflect the means +/- SD of 3 independent experiments.
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BMC Molecular Biology 2008, 9:30 http://www.biomedcentral.com/1471-2199/9/30CpG island [33]. Consensus sites for the transcription fac-
tor Sp1 are overrepresented in promoters with high CG
content, and Sp1 is capable of recruiting TATA-binding
protein in the absence of TATA boxes [51]. We have stud-
ied the role of two Sp1 consensus sites close to TSS B and
found that mutation of these sites did not affect the
reporter gene activity of promoter region B. This result
does not exclude a regulatory role of Sp1, since other Sp1
sites are present further upstream (Figure S1).
The use of alternative promoters allows for a more com-
plex regulation of gene expression. Two different, non-
overlapping fragments of the DYRK1A promoter region
are capable of driving reporter gene expression. The higher
activity of promoter region A was not specific to Saos2
cells, but was also observed in other cell lines (HeLa, COS-
7, PC3, PC-12, data not shown), arguing against the pos-
sibility that the two promoters bring about tissue-specific
transcriptional regulation. In accordance with this obser-
vation, the CAGE tag analysis also revealed no tissue-spe-
cificity in the composition of the different tag clusters (not
shown). However, the two promoter regions differed
strikingly in their response to overexpression of E2F1. All
promoter constructs driven by promoter B were stimu-
lated by E2F1, but none of the constructs that contained
TSS A showed a significant response. Although promoter
region A was still more active than promoter region B,
total levels of DYRK1A mRNA were increased by E2F1
overexpression in Phoenix cells and Saos2 cells.
E2F transcription factors are well known to regulate
numerous genes essential for DNA replication and cell
cycle progression, and also DNA damage repair, apopto-
sis, development and differentiation [52]. Although so far
no study has directly addressed the function of DYRK1A
in the cell cycle, DYRK1A mRNA levels were repeatedly
found to be regulated in systems of cellular differentiation
and proliferation (see introduction). Consistent with a
role in cell cycle regulation or apoptosis, DYRK1A was
identified among the 150 genes whose pattern of expres-
sion in human leukemia cells most accurately discrimi-
nated responses of patients to cytostatic agents [53].
Interestingly, in transgenic mice DYRK1A overexpression
has been described to be associated with high levels of
cyclin B1 [54]. On the other hand, DYRK1A overexpres-
sion has been shown to enhance nerve growth factor
(NGF)-mediated neuronal differentiation of PC12 cells
[55]. Many E2F1 target genes including the homeobox
genes are involved in developmental regulation [52],
which is another area where DYRK1A has been implicated
[56]. Further research is required to clarify the conse-
quences of DYRK1A upregulation by E2F1.
Mutation of the only potential E2F binding site in front of
TSS B did not affect E2F1-induced reporter gene activity.
However, it is well known that some genes are regulated
by E2F factors in the absence of canonical E2F sites
[46,57,58]. For transcriptional activation of the human
ASK gene, binding of E2F to a non-consensus site depends
on the presence of a neighboring Sp1 site [46]. We have
therefore also mutated the two Sp1 sites closest to TSS B
but detected no effect on basal or E2F-induced promoter
activity. Still, E2F1 can also bind to GC-rich elements in
the absence of consensus E2F consensus elements, and the
mutated -742 construct still contained several potential
Sp1 sites [59]. Thus, our results neither exclude the possi-
bility that E2F1 acts via binding to a non-consensus E2F
site nor that its effect is mediated indirectly by activation
or upregulation of other transcription factors.
In addition to E2F1, we tested CREB for its potential role
in the regulation of the DYRK1A promoter because Dyrk1a
was detected as a target gene of CREB in a chromatin
immunoprecipitation-based screen in rat PC12 cells [47].
A potential CRE is located 50 bp upstream of human TSS
A and is conserved in the mouse promoter. Although the
motif in the DYRK1A promoter does not exactly match the
CRE consensus sequence, it contains two copies of the
CRE half site (CGTCA), which binds CREB with a lower
affinity and is found in about half of the genes with func-
tional CREs [49]. In fact, binding of CREB to this sequence
in electrophoretic mobility shift assays was much weaker
than binding to a consensus CRE (Figure S4 in the Addi-
tional file 1 "supplementary figures"). Forskolin did not
enhance promoter activity in several cell lines, and Dyrk1a
mRNA levels were not increased in forskolin-treated PC12
cells. Thus, it appears unlikely that CREB is a major tran-
scriptional regulator of human or rat DYRK1A/Dyrk1a.
However, we cannot totally exclude that the lack of a
CREB effect in our hands is due to heterogeneity of PC12
subclones in different labs, or slightly divergent experi-
mental conditions.
Up to now, the only transcription factor reported to regu-
late the DYRK1A promoter was AP4 (activator protein 4),
which was described to negatively regulate expression of
DYRK1A in non-neural cells [60]. It remains to be deter-
mined by which regulatory mechanisms, in addition to
transcriptional control by E2F1 and AP4, expression levels
of DYRK1A are controlled.
Conclusion
The present results show that transcription of the human
DYRK1A gene is controlled by two promoters that differ in
their strength and regulation by E2F1. This finding reveals
a previously unknown level of complexity in the regula-
tion of expression of the DYRK1A gene, and provides the
basis for further studies of its transcriptional regulation.
The identification of E2F1 as a regulator of DYRK1A
expression is consistent with the presumed function of thePage 11 of 16
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Forskolin does not alter expression of DYRK1Aigure 8
Forskolin does not alter expression of DYRK1A. A) Potential cAMP responsive element (CRE) upstream of TSS A. The 
sequence shown is fully conserved in the mouse, dog, and platypus genomes and comprises a full CRE sequence (with one mis-
match to the canonical octamer) and a CRE half-site (boxed). B) Forskolin stimulates phosphorylation of CREB on Ser133. 
PC12 cells were treated for 30 min with forskolin (10 μM) or DMSO (Ctrl) before nuclear extracts were prepared. Phospho-
Ser133 in CREB was detected by Western blot analysis with the help of a phosphospecific antibody. Migration of molecular 
mass standards is indicated in kDa. C) Northern blot. PC12 cells were treated for 24 h with forskolin (10 μM) or DMSO as the 
vehicle (Ctrl) before total RNA was isolated and subjected to Northern blot analysis with probes for DYRK1A, glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), and c-fos. Duplicate lanes contain RNA samples from parallel plates. Migration of the 
ribosomal RNAs is indicated in the right margin (28S, 18S). D) Luciferase assays. The indicated cell lines (PC12, PC3, Saos2) 
were transfected with the reporter gene constructs as schematically depicted. Luciferase activity was determined from cells 
treated with forskolin (10 μM) for 24 h and from untreated cells. Data were normalized to β-galactosidase activity and are pre-
sented as fold induction relative to untreated cells. Bars reflect the means +/- SD of 3 independent experiments (Saos2, PC3) 
or the means of duplicate wells for the experiment with PC12 cells.
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BMC Molecular Biology 2008, 9:30 http://www.biomedcentral.com/1471-2199/9/30kinase in the regulation of cell proliferation and differen-
tiation. Subtle changes in cell cycle regulation may affect
brain development in Down syndrome, because neuro-
genesis involves proliferation and differentiation and is
closely linked to the cell cycle [61].
Methods
Rapid amplification of cDNA ends (RACE)
The Marathon-Ready RACE RLM kit (Clontech, Mountain
View, CA) was used for 5'-RACE of the human DYRK1A
transcript on cDNA from the human PC3 prostate carci-
noma cell line (Marathon-ready cDNA, Clontech). Two
nested reverse primers were designed to match the second
coding exon (exon 3 in Figure 1, primer sequences are
given in the Additional file 2 "vector construction and oli-
gonucleotide sequences"). PCR products were cloned, and
the clones with the longest inserts were preferentially
selected for sequencing.
Database mining
The data on the chromatin structure were taken from the
ChIP-Seq data generated by Barski et al. [34,62]. The
CAGE database was searched with the help of the CAGE
basic viewer [63]. Exact start positions for all tags mapped
to a region of 1,000 bp upstream of TSS B were extracted
from the information linked to the individual tag clusters.
Analyses of the gene structure are based on the public ver-
sion of the human genome [64]. Transcription start sites
predicted by the eponine program [65] are also provided
by the UCSC server.
Reporter gene vectors
All human promoter constructs were obtained by PCR
cloning from genomic DNA isolated from human
HEK293 cells. A list of all primers and details of the clon-
ing procedure are given in the Additional file 2 "vector
construction and oligonucleotide sequences". Point
mutations were introduced with the help of Quik-
Change™ Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, CA) and verified by sequencing. Murine promoter
fragments were subcloned from a BAC clone (clone ID
RP24-223C1 in the NCBI clone registry) into pGL3-basic
using suitable restriction sites within the promoter region
(SacI – BamHI fragment from -982 to -660, BamHI-XhoI
fragment from -660 to +24, numbered relative to human
TSS B). As a positive control for CREB activation, we used
pCRE-Luc (Stratagene, La Jolla, CA) which contains 4 cop-
ies of the CRE enhancer element (AGCCTGACGTCA-
GAG)4.
Cell culture and transfection
The human PC3 prostate carcinoma cell line was pur-
chased from the DSMZ (Braunschweig, Germany) (DSMZ
No. ACC 465) and grown in 45% RPMI 1640/45% Ham's
F12 medium supplemented with 10% fetal calf serum.
Saos2 cells and Phoenix™ cells were grown in Dulbecco's
modified Eagle's medium (DMEM) with high glucose (4.5
g/l) supplemented with sodium pyruvate (1 mM), L-
glutamine (4 mM) and 10% fetal calf serum. PC12 cells
(kindly provided by Günther Schmalzing, Institute of
Pharmacology, RWTH Aachen University) were also
grown in DMEM with high glucose, sodium pyruvate and
glutamine but with 10% horse serum and 5% fetal calf
serum. The cells from this subclone attach well on plastic
dishes and form small dendrites already in the absence of
nerve growth factor (NGF). A second PC12 subclone,
which needed collagen coating for adherent growth and
showed minimal neuronal phenotype without NGF, was
obtained from Jan Tavernier (Flanders Interuniversity
Institute for Biotechnology, Ghent, Belgium). Media and
serum were purchased from PAA Laboratories (Linz, Aus-
tria). Transient transfections were carried out with
FuGENE 6 transfection reagent (Roche Diagnostics, Man-
nheim, Germany) according to the manufacturer's
instructions.
Luciferase assays
Saos2 or PC3 cells were seeded in 6-well plates (200.000
cells/well) and transfected with the various luciferase vec-
tors (0.1 μg) and 0.25 μg of the pSVβ-gal control plasmid
(Promega, Madison, WI, USA). Two days after transfec-
tion, cells were washed in PBS and then harvested in
reporter lysis buffer (Promega). PC12 cells were seeded at
a density of 600.000 cells/well. In some experiments, for-
skolin (10 μM; Merck-Calbiochem, Darmstadt, Germany)
or vehicle (dimethyl sulfoxide) was added one day after
transfection for 24 h before cell lysis (Figure 8). For exper-
iments involving induction of E2F1, doxycyclin (2 μg/ml)
was added 5 h after transfection, and cells were lysed 17 h
later.
Luciferase activities were measured from duplicate wells
with the help of a commercial kit (Promega) and data
were normalized to β-galactosidase activities. β-galactosi-
dase activities were determined by the luminescent galac-
tosidase detection kit II (Clontech). The protein
concentration of the cell lysates was measured using the
BCA protein kit (Pierce, Rockford, IL, USA).
Overexpression of E2F1
A plasmid for transient mammalian expression of
untagged, full length human E2F1 (pCMV-SPORT6) was
purchased from the Resource center/Primary Database
(RZPD, Berlin) ([GenBank:BC050369], clone
IMAGE:6025053). A stably transfected Saos2 cell clone
expressing E2F1 under the control of a tetracycline-regu-
lated promoter [43] was kindly provided by Karen Vous-
den (Beatson Cancer Institute, Glasgow, UK).Page 13 of 16
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Total RNA from cells cultured in 10 cm-plates was isolated
using the RNeasy Midi Kit (Qiagen, Hilden, Germany).
Samples (15 μg) of total RNA were separated by denatur-
ating formaldehyde electrophoresis on 1% (w/v) agarose
gels and transferred by capillary blot onto positively
charged nylon membranes (Hybond N+; Amersham,
Freiburg, Germany). As the probe for DYRK1A, a 1,400 bp
EcoRI fragment from the 5'-end of the human DYRK1A
cDNA was labeled with 32P by random oligonucleotide
priming. After probe removal by incubation with 0.5%
SDS at 100°C, blots were rehybridized with a probes spe-
cific for glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (kind gift of Claudia Krusche, Aachen) and c-
fos. To generate the template for a c-fos-specific probe, the
cDNA encoding the open reading frame of rat c-fos was
amplified with specific primers, cloned and sequenced.
For Western blot analysis of CREB phosphorylation,
nuclear extracts were prepared from PC12 cells by hypot-
onic lysis [66]. Forskolin was added at a final concentra-
tion of 10 μM to some of the samples as indicated in the
figure legend. For Western blot analysis, protein samples
were separated by SDS-PAGE (10% gel), blotted onto
nitrocellulose, and phosphorylation of CREB on Ser133
was detected by chemiluminescence using a phosphospe-
cific antibody (Upstate, Charlottesville, VA) and horserad-
ish peroxidase-labeled secondary antibody (Pierce,
Rockford, IL).
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